Rapid functional cell-based activity profiling of multi-receptor targeted anti-obesity therapies

Supported by:

2 October 2024

3:00pm

Shares

0

Share via

• Facebook
• Like
• Twitter
• Pinterest
• LinkedIn
• Digg
• Del
• Tumblr
• VKontakte
• Print
• Email
• Reddit
• Buffer
• Love This
• Weibo
• Pocket
• Xing
• Odnoklassniki
• WhatsApp
• Meneame
• Blogger
• Amazon
• Yahoo Mail
• Gmail
• AOL
• Newsvine
• HackerNews
• Evernote
• MySpace
• Mail.ru
• Viadeo
• Line
• Flipboard
• Comments
• Yummly
• SMS
• Viber
• Telegram
• Subscribe
• Skype
• Facebook Messenger
• Kakao
• LiveJournal
• Yammer
• Edgar
• Fintel
• Mix
• Instapaper
• Copy Link

Obesity is a serious, chronic disease currently affecting about 38 percent of the global population. This is expected to rise to over 50 percent by 2035 according to a recent report from the World Obesity Atlas (WOA). Single GLP-1R agonist, Semaglutide (Novo-Nordisk), recently spiked market interest as an approved drug for obesity management.

Now, many pharmaceutical companies are pursuing a strategy of targeting multiple receptors simultaneously for additive benefits, the most attractive of these being dual GLP-1R/GIPR agonist, Tirzepatide (approved drug developed by Eli Lilly), and triple GLP-1R/GIPR/GCGR agonist,

Retatrutide (in clinical development by Eli Lilly). With anti-obesity target combination therapies quickly gaining market interest, the need for a focused set of cell-based assays ideal for testing functional activity of desired therapies against multiple disease-relevant targets in one convenient screen became apparent. Eurofins Discovery will demonstrate the use of a single platform of cell-based assays to characterise anti-obesity compounds against relevant metabolic targets for specificity, potency and biased signalling with services such as obesityLITE, gpcrMAX and gpcrBIAS.

Key learning points

• Learn how a single platform of cell-based assays can be used to profile compounds for specificity, potency and signalling mechanism against obesity related targets.
• Learn how leading anti-obesity peptides semaglutide, tirzepatide and retatrutide were profiled for specificity in the obesityLITE panel of cell-based assays of obesity related receptors in β-arrestin and second messenger signalling (GPCR) or receptor dimerisation (cytokine).
• Understand data showing each drug demonstrating highly specific responses for reported targets (semaglutide: GLP1R; tirzepatide: GLP1R/GIPR; retatrutide: GLP1R/GIPR/GCGR) in both β-arrestin and cAMP formats.
• Learn how biased signalling at GLP1R was evaluated.
• Understand how semaglutide was demonstrated to be highly specific for agonistic activity at GLP1R by profiling against 168 GPCR targets in agonist and antagonist modes in the gpcrMAX panel.

• Ask our expert speaker questions regarding the case studies and data presented

Register to join this webinar for free

OUR SPEAKER

Luke Oostdyk, PhD, Associate Study Director, LeadHunter Services California, Eurofins Discovery

Dr Luke Oostdyk, PhD, is an Associate Study Director at Eurofins Discovery and part of the LeadHunter Discovery Services team in Fremont, California. Luke completed his graduate studies in biochemistry and genetics at the University of Virginia where he identified novel functions and regulation of the nuclear transport factor KPNA7 and investigated the impact of epilepsy-associated mutations on receptor function and biology. After moving to industry, he spent three years as a scientist performing routine screening and assay development of cell-based assays for customers at Eurofins Discovery, including HTS, H2L and SAR programmes. In his current role, Luke aids customers with the design and execution of studies using LeadHunter Discovery Services portfolio of cell-based assays.

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 2nd October at 16:00 BST

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.